111 (YI) Return on Invested Capital (2024 - 2025)
111's (YI) quarterly Return on Invested Capital came in at 0.0% in Q4 2025, little changed year-on-year from 0.0% in Q4 2024, and up 14013.16% quarter-over-quarter from 0.0% in Q3 2025.
111 (YI) Return on Invested Capital (2024 - 2025) Analysis & Trends
111 has disclosed Return on Invested Capital across 2 years of filings, most recently posting 0.0% for Q4 2025.
- Return on Invested Capital for Q4 2025 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.0% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
- Return on Invested Capital came in at 0.0% for Q4 2025 at 111, up from 0.0% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 0.01% in Q1 2024 to a low of 0.0% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | - |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | 0.01% |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | 0.00% |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | 0.00% |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | 0.00% |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | 0.00% |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | -0.02% |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | 0.00% |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | 0.00% |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 0.00% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | 0.00% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | 0.01% |